Taking people in United StatesNo phase

Parathyroidectomy and Mobility Study

Key facts

Who runs it: University of Florida
Where: Gainesville, United StatesSee the site
Trial code: NCT07103876
Status: Recruiting
People taking part: 80 people, planned
Started: 15 Aug 2025
Expected to end: 31 Mar 2027
Type of study: Observational
Record updated: 15 September 2026

Who can take part

Age: 60 years to 100 years
Sex: Women and men
Healthy volunteers: Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Other criteria

Inclusion:
Age ≥ 60 years
Biochemical diagnosis of hypercalcemic (corrected serum calcium >10.2 mg/dL or ionized serum calcium >1.31 mmol/dL or 5.2 mg/dL on at least one serum sample) primary hyperparathyroidism as determined by board-certified endocrinologist or endocrine surgeon
Undergoing parathyroidectomy at UF Health
Willing and able to give informed consent; Exclusion:
Failure to provide informed consent
Biochemical diagnosis of eucalcemic primary hyperparathyroidism (corrected serum calcium ≤10.2 mg/dL or ionized serum calcium ≤1.31 mmol/dL or 5.2 mg/dL on at least one serum sample)
Elected not to undergo parathyroidectomy at UF Health
Major surgery as deemed by principal investigator or hip/knee replacement in the past 6 months
Fractures to the hands, arms or legs within the last 6 months
Traumatic accident (i.e. motor vehicle collision, fall from elevation, etc.) resulting in orthopedic trauma or requiring prolonged immobilization (>2 weeks) within the last 6 months
Blood transfusion within the past 3 months
Self-reported myocardial infarction, cerebrovascular accident, or unstable angina within the past 6 months
NYHA Class 3 or 4 congestive heart failure
Major psychiatric disorder
Cancer requiring treatment in the past 1 year (including metastatic cancer), except for locally treated non-melanoma skin cancers or cancers that have clearly been cured or in the opinion of the investigator carry an excellent prognosis (e.g., Stage 1 cervical cancer)
Renal failure requiring hemodialysis or peritoneal dialysis
Use of bone-modifying therapies (alendronate [Fosamax], zoledronic acid [Reclast], denosumab [Prolia or Xgeva], or romosozumab [Evenity]) within 1 month of planned surgery
Planning to permanently leave the area within 3 months of parathyroidectomy
Vision or hearing impairment - defined as unable to read or listen/follow instructions despite the use of maximal assistive devices (i.e. contact lenses, glasses, hearing aids, etc.)
Participating in another clinical trial or has received an investigational product within 30 days prior to screening/enrollment

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 60 and 100 years old?

Where in United States

Clinical and Translational Research BuildingGainesville, United StatesContact: Recruitment CoordinatorsTaking people

About the trial

What the trial wants to find out

This study evaluates whether surgical removal of the parathyroid gland (parathyroidectomy) improves physical function and mobility in older adults with primary hyperparathyroidism (PHPT). PHPT, a common endocrine disorder in older adults, is associated with reduced muscle strength, mobility, and quality of life. This prospective observational study will enroll up to 80 participants aged 60 and older undergoing parathyroidectomy at UF Health. Participants will complete physical performance tests, wear an Actigraph device to assess physical activity, and provide blood samples for biomarker analysis at pre- and post-operative time points. The goal is to characterize changes in physical function and activity following surgery and to identify biomarkers that may predict mobility improvements. Findings will help inform future larger-scale studies and could expand surgical indications for PHPT in older adults.